139 related articles for article (PubMed ID: 30616469)
21. Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas.
Manconi L; Coviello E; Canale F; Giannoni L; Minetto P; Guolo F; Clavio M; Marcolin R; Cea M; Cagnetta A; Gobbi M; Miglino M; Ballerini F; Lemoli RM
Leuk Lymphoma; 2020 Jan; 61(1):84-90. PubMed ID: 31480933
[TBL] [Abstract][Full Text] [Related]
22. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
Martín A; Redondo AM; Dlouhy I; Salar A; González-Barca E; Canales M; Montes-Moreno S; Ocio EM; López-Guillermo A; Caballero D;
Br J Haematol; 2016 Apr; 173(2):245-52. PubMed ID: 26847165
[TBL] [Abstract][Full Text] [Related]
23. [Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma].
Li YH; Jiang WQ; Huang HQ; Zhang L; Liu DG; Xu RH; Zhou ZM; Sun XF; Lin TY; Xu GC; He YJ; Guang ZZ
Ai Zheng; 2002 Aug; 21(8):900-2. PubMed ID: 12478903
[TBL] [Abstract][Full Text] [Related]
24. Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas.
Kroschinsky F; Röllig D; Riemer B; Kramer M; Ordemann R; Schetelig J; Bornhäuser M; Ehninger G; Hänel M
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3067-3073. PubMed ID: 31563974
[TBL] [Abstract][Full Text] [Related]
25. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
[TBL] [Abstract][Full Text] [Related]
26. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation.
Press OW; Livingston R; Mortimer J; Collins C; Appelbaum F
J Clin Oncol; 1991 Mar; 9(3):423-31. PubMed ID: 1999711
[TBL] [Abstract][Full Text] [Related]
27. A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.
Lim ST; Fayad L; Tulpule A; Modiano M; Cabanillas F; Laffranchi B; Allievi C; Bernareggi A; Levine AM
Leuk Lymphoma; 2007 Feb; 48(2):374-80. PubMed ID: 17325899
[TBL] [Abstract][Full Text] [Related]
28. Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapy.
Abdayem P; Ibrahim N; El Dakdouki Y; Willekens C; Ghez D; A Rouche J; Dartigues P; Desmaris R; Danu A; Rossignol J; Lazarovici J; Fermé C; Ribrag V; Michot JM
Eur J Haematol; 2021 Apr; 106(4):574-583. PubMed ID: 33512026
[TBL] [Abstract][Full Text] [Related]
29. Successful use of full-dose dexamethasone, high-dose cytarabine, and cisplatin as part of initial therapy in non-hodgkin and hodgkin lymphoma with severe hepatic dysfunction.
McCarthy J; Gopal AK
Clin Lymphoma Myeloma; 2009 Apr; 9(2):167-70. PubMed ID: 19406729
[TBL] [Abstract][Full Text] [Related]
30. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
31. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD;
Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
33. Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?
Gisselbrecht C
Hematology Am Soc Hematol Educ Program; 2012; 2012():410-6. PubMed ID: 23233612
[TBL] [Abstract][Full Text] [Related]
34. Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma.
Puig N; Wang L; Seshadri T; al-Farsi K; Keating A; Crump M; Kuruvilla J
Leuk Lymphoma; 2013 Mar; 54(3):507-13. PubMed ID: 22897731
[TBL] [Abstract][Full Text] [Related]
35. Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma.
Machover D; Delmas-Marsalet B; Misra SC; Gumus Y; Goldschmidt E; Schilf A; Frénoy N; Emile JF; Debuire B; Guettier C; Farrokhi P; Boulefdaoui B; Norol F; Parquet N; Ulusakarya A; Jasmin C
Ann Oncol; 2001 Oct; 12(10):1439-43. PubMed ID: 11762817
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of modified rituximab-ESHAP therapy for relapsed/refractory B-cell lymphoma.
Ueda K; Nannya Y; Asai T; Yamamoto G; Hangaishi A; Takahashi T; Imai T; Kurokawa M
J Chemother; 2010 Feb; 22(1):54-7. PubMed ID: 20227994
[TBL] [Abstract][Full Text] [Related]
37. [Outpatient reinduction therapy with gemcitabine, dexamethasone, Cisplatin (GDP) for patients with relapsed and refractory lymphoma].
Aota Y; Tanaka M; Watanabe N; Tomomatu J; Gotoh A; Komatu N
Gan To Kagaku Ryoho; 2015 Jan; 42(1):51-5. PubMed ID: 25596679
[TBL] [Abstract][Full Text] [Related]
38. Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed/refractory lymphoma patients.
Tixier F; Ranchon F; Iltis A; Vantard N; Schwiertz V; Bachy E; Bouafia-Sauvy F; Sarkozy C; Tournamille JF; Gyan E; Salles G; Rioufol C
Hematol Oncol; 2017 Dec; 35(4):584-590. PubMed ID: 27377614
[TBL] [Abstract][Full Text] [Related]
39. [NAPD regimen for patients with recurrent refractory diffuse large B-cell lymphoma].
Huang C; Wu H; Zhu H; Liu L; Tian R; Xu C; Li X; Wang L; Cao K; Cao P
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 43(7):754-759. PubMed ID: 30124211
[TBL] [Abstract][Full Text] [Related]
40. Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group.
Giebel S; Sadus-Wojciechowska M; Halaburda K; Drozd-Sokolowska J; Wierzbowska A; Najda J; Mendrek W; Sobczyk-Kruszelnicka M; Nowicki M; Holowiecki J; Czerw T
Ann Hematol; 2016 Jan; 95(2):263-9. PubMed ID: 26611854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
